|
|
 |
The Schimmer lab is interested in drug discovery for hematologic malignancies with a focus on leukemia. The group has used functional genomic approaches to identify mechanisms of drug action and identify new therapeutic targets for acute leukemia. In addition, they are used drug repurposing approaches to advance drugs into clinical trial for patients with refractory hematologic malignancies
|
|
Researcher Information
Staff Physician and Senior Scientist
|
|
|
Senior Scientist, Ontario Cancer Institute, Princess Margaret Hospital
2010-present
Associate Professor, Dept. Medical Biophysics, Faculty of Medicine, University of Toronto
2009-present
Associate Professor, Department of Medicine, Faculty of Medicine, University of Toronto
2009-present
|
|
Researcher Information
Staff Physician and Senior Scientist
|
|
|
|
Sharmeen S, Skrtic M, Sukhai MA, Hurren R, Gronda M, Wang X, Fonseca SB, Sun H, Wood TE, Ward R, Minden MD, Batey RA, Datti A, Wrana J, Kelley SO, Schimmer AD. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood 2010;116(18):3593-3603.
|
|
|
Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD. Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst 2010;102(14):1069-1082.
|
|
|
Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010;115(23):4824-4833.
|
|
|
Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick J, Schimmer AD. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009;114(14):3064-3073.
|
|
|
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009;27(28):4741-4746.
|
|
|
Researcher Information
Staff Physician and Senior Scientist
|
|
|
ORGANIZATIONS
PROJECTS
There are no related projects for this profile.
RESOURCES
There are no related resources for this profile.
ATTACHMENTS
There are no downloads available for this profile.
OTHER INFORMATION
There is no other information available for this profile.
|
|
|
|
|
|
YOU MAY ALSO BE INTERESTED IN:
CATEGORIES
Disciplinary Focus
Clinical science,
Experimental biology and chemistry
Core Technology
Nucleic acids:
Gene expression systems,
RNA technologies
Sign-up to edit this profile
|
